KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.00

Soluble suppression of tumorigenicity 2 (sST2) dynamics are associated with delayed hospital discharge in patients with COVID-19: a joint-modelling analysis of the DisCoVeRy trial's longitudinal data.

Clément R Massonnaud, Maya Hites, Aurélien Philippe, Nathan Peiffer-Smadja, Jeanne Rancic, Yazdan Yazdanpanah, Sophie Luneau, Annabelle Dupont, Christelle Delmas, Jean-Luc Diehl, Sophie Susen, DisCoVeRy Study group, France Mentré, Florence Ader, David M Smadja

Clin Microbiol Infect S1198-743X(26)00418-0

PMID42567228
PMCID-
DOI10.1016/j.cmi.2026.07.051
发表日期2026-08-07
入排依据:未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
摘要

摘要

OBJECTIVES: Identifying robust biomarkers reflecting thromboinflammation, endothelial injury, angiogenesis, and fibrosis that predict clinical recovery remains challenging. Although several biomarkers are associated with disease severity, the added value of their longitudinal dynamics beyond established markers is unclear. We assessed the association between biomarker trajectories and time to hospital discharge in hospitalized patients with COVID-19. METHODS: We analysed hospitalized adults with PCR-confirmed SARS-CoV-2 infection enrolled in the DisCoVeRy randomized trial. Blood samples were collected at baseline and days 3, 5, 8, and 11 to measure D-dimer and 12 biomarkers. The primary outcome was time to hospital discharge by day 29, with death as a competing risk. Bayesian joint models combining linear mixed-effects models for biomarker trajectories and cause-specific Cox models were adjusted for baseline severity, ISARIC Coronavirus Clinical Characterisation Consortium (ISARIC 4C) score, and treatment arm. Models included D-dimer alone and each biomarker added individually. Results are reported as adjusted hazard ratios with 95% credibility intervals (CrIs). RESULTS: Of the 603 participants randomly divided, 492 had at least one sample measured, 32% (155/492) had a severe disease, and 5.5% (27/492) died before day 29. Of all biomarkers, only soluble suppression of tumorigenicity 2 (sST2) was still associated with time-to-discharge in multivariate analysis after adjusting baseline covariates (adjusted hazard ratio: 0.26; 95% CrI: [0.17-0.41]; p <10-4). A level of sST2 twice as high leads to a 33% (95% CrI: [24%; 41%]) lower instantaneous probability of discharge. D-dimer was significantly associated with time-to-discharge in the null model (0.37 [0.23-0.58]; p <10-4), but not when including sST2 (0.68 [0.42-1.07]; p 0.09). CONCLUSIONS: Longitudinal sST2 dynamics were associated with delayed hospital discharge before day 29 and provided better prognostic information than D-dimer. By integrating signals of inflammation, endothelial injury, and tissue remodelling, sST2 may serve as a biomarker of impaired recovery and a potential tool for risk stratification and clinical decision support. External validation by prospective studies is needed to confirm our findings.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。